| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | ||
| 3 | Generic | parsaclisib | |
| 4 | Indication | AIHA, R/R FL, Myelofibrosis | |
| 5 | MOA | PI3Kdelta | |
| 6 | Clinical Trials | ||
| 7 | Phase I "CITADEL-102" | ||
| 8 | |||
| 9 | Phase I "CITADEL-112" | ||
| 10 | |||
| 11 | |||
| 12 | Phase III "LIMBER-313" 1L MF with ruxolitinib | ||
| 13 | |||
| 14 | Phase III "LIMBER-304" suboptimal ruxolitinib responders | ||
| 15 | |||
| 16 | |||
| 17 | Phase III "PATHWAY" AIHA |